Therapy of hypoparathyroidism with intact parathyroid hormone.

Rubin MR, Sliney J Jr, McMahon DJ, Silverberg SJ, Bilezikian JP

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA22 Jan 2010Cited by 85 (Europe PMC)

PMID20094706PMCIDPMC2947814DOI10.1007/s00198-009-1149-xPepBankPUB-20094706

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In hypoparathyroid subjects, PTH(1-84) reduced supplemental calcium requirements from 3,030±2,325 to 1,661±1,267 mg/day.
In plain wordsIn people with hypoparathyroidism, calcium supplement requirements fell during PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseSupplemental calcium requirement
Study
n = 30
Comparator
Baseline
Outcome group
Supplement requirements · Endocrine and hormones
Studied dose
100 µg every other day · subcutaneous · 24 monthsAs given in this study (human).
Measurements
Supplemental calcium requirement
3030 mg/day
before PTH(1-84); mean, SD 2,325
Supplemental calcium requirement
1661 mg/day
after PTH(1-84) treatment; mean, SD 1,267
Source sentences
Summary
Requirements for supplemental calcium decreased significantly (3,030±2,325 to 1,661±1,267 mg/day (mean±SD); p<0.05), as did requirements for supplemental 1,25-dihydroxyvitamin D (0.68±0.5 to 0.40±0.5 µg/day; p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty subjects with hypoparathyroidism were treated in an open-label study of PTH(1-84) 100 µg every other day by subcutaneous injection for 24 months, with monitoring of calcium and vitamin D supplementation requirements, serum and 24 h urinary calcium excretion, and BMD by dual energy X-ray absorptiometry.
Report a problemFND-2009470601
02HumanNon-randomized trialEfficacy outcome
In hypoparathyroid subjects, PTH(1-84) reduced supplemental 1,25-dihydroxyvitamin D requirements from 0.68±0.5 to 0.40±0.5 µg/day.
In plain wordsIn people with hypoparathyroidism, active vitamin D supplement requirements fell during PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseSupplemental active vitamin D requirement
Study
n = 30
Comparator
Baseline
Outcome group
Supplement requirements · Endocrine and hormones
Studied dose
100 µg every other day · subcutaneous · 24 monthsAs given in this study (human).
Measurements
Supplemental 1,25-dihydroxyvitamin D requirement
0.68 µg/day
before PTH(1-84); mean, SD 0.5
Supplemental 1,25-dihydroxyvitamin D requirement
0.4 µg/day
after PTH(1-84) treatment; mean, SD 0.5
Source sentences
Summary
Requirements for supplemental calcium decreased significantly (3,030±2,325 to 1,661±1,267 mg/day (mean±SD); p<0.05), as did requirements for supplemental 1,25-dihydroxyvitamin D (0.68±0.5 to 0.40±0.5 µg/day; p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty subjects with hypoparathyroidism were treated in an open-label study of PTH(1-84) 100 µg every other day by subcutaneous injection for 24 months, with monitoring of calcium and vitamin D supplementation requirements, serum and 24 h urinary calcium excretion, and BMD by dual energy X-ray absorptiometry.
Report a problemFND-2009470602
03HumanNon-randomized trialEfficacy outcome
In hypoparathyroid subjects, serum calcium was mostly unchanged at 24 months of PTH(1-84) treatment.
In plain wordsIn people with hypoparathyroidism, blood calcium was mostly unchanged after 24 months of PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
Direction not reportedSerum calcium
Study
n = 30
Comparator
Baseline
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
100 µg every other day · subcutaneous · 24 monthsAs given in this study (human).
Source sentences
Summary
Serum calcium levels and 24 h urinary calcium excretion were mostly unchanged at 24 months.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty subjects with hypoparathyroidism were treated in an open-label study of PTH(1-84) 100 µg every other day by subcutaneous injection for 24 months, with monitoring of calcium and vitamin D supplementation requirements, serum and 24 h urinary calcium excretion, and BMD by dual energy X-ray absorptiometry.
Report a problemFND-2009470603
04HumanNon-randomized trialEfficacy outcome
In hypoparathyroid subjects, urinary calcium excretion was mostly unchanged at 24 months of PTH(1-84) treatment.
In plain wordsIn people with hypoparathyroidism, urinary calcium was mostly unchanged after 24 months of PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
Direction not reported24 h urinary calcium excretion
Study
n = 30
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 µg every other day · subcutaneous · 24 monthsAs given in this study (human).
Source sentences
Summary
Serum calcium levels and 24 h urinary calcium excretion were mostly unchanged at 24 months.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty subjects with hypoparathyroidism were treated in an open-label study of PTH(1-84) 100 µg every other day by subcutaneous injection for 24 months, with monitoring of calcium and vitamin D supplementation requirements, serum and 24 h urinary calcium excretion, and BMD by dual energy X-ray absorptiometry.
Report a problemFND-2009470604
05HumanNon-randomized trialEfficacy outcome
In hypoparathyroid subjects, lumbar spine BMD increased by 2.9±4% from baseline during PTH(1-84) treatment.
In plain wordsIn people with hypoparathyroidism, spine bone density increased from baseline during PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseLumbar spine BMD
Study
n = 30
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg every other day · subcutaneous · 24 monthsAs given in this study (human).
Measurements
Change in lumbar spine BMD from baseline
2.9%
mean ± SD 4%; p<0.05
Source sentences
Summary
BMD increased at the lumbar spine by 2.9±4% from baseline (p<0.05), while femoral neck BMD remained unchanged and distal one third radial BMD decreased by 2.4±4% (p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty subjects with hypoparathyroidism were treated in an open-label study of PTH(1-84) 100 µg every other day by subcutaneous injection for 24 months, with monitoring of calcium and vitamin D supplementation requirements, serum and 24 h urinary calcium excretion, and BMD by dual energy X-ray absorptiometry.
Report a problemFND-2009470605
06HumanNon-randomized trialEfficacy outcome
In hypoparathyroid subjects, femoral neck BMD remained unchanged during PTH(1-84) treatment.
In plain wordsIn people with hypoparathyroidism, femoral neck bone density remained unchanged during PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeFemoral neck BMD
Study
n = 30
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg every other day · subcutaneous · 24 monthsAs given in this study (human).
Source sentences
Summary
BMD increased at the lumbar spine by 2.9±4% from baseline (p<0.05), while femoral neck BMD remained unchanged and distal one third radial BMD decreased by 2.4±4% (p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty subjects with hypoparathyroidism were treated in an open-label study of PTH(1-84) 100 µg every other day by subcutaneous injection for 24 months, with monitoring of calcium and vitamin D supplementation requirements, serum and 24 h urinary calcium excretion, and BMD by dual energy X-ray absorptiometry.
Report a problemFND-2009470606
07HumanNon-randomized trialEfficacy outcome
In hypoparathyroid subjects, distal one third radial BMD decreased by 2.4±4% during PTH(1-84) treatment.
In plain wordsIn people with hypoparathyroidism, forearm bone density decreased during PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseDistal one third radial BMD
Study
n = 30
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg every other day · subcutaneous · 24 monthsAs given in this study (human).
Measurements
Change in distal one third radial BMD from baseline
−2.4%
mean ± SD 4%; p<0.05
Source sentences
Summary
BMD increased at the lumbar spine by 2.9±4% from baseline (p<0.05), while femoral neck BMD remained unchanged and distal one third radial BMD decreased by 2.4±4% (p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty subjects with hypoparathyroidism were treated in an open-label study of PTH(1-84) 100 µg every other day by subcutaneous injection for 24 months, with monitoring of calcium and vitamin D supplementation requirements, serum and 24 h urinary calcium excretion, and BMD by dual energy X-ray absorptiometry.
Report a problemFND-2009470607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01199614

HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism

Columbia Universityn = 62Dec 2009 to 26 Jun 2017

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 5 Jul 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.